Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Hydrochlorthiazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochlorthiazide SCHEMBL15656554 | 0.97 | — | — | |
| Hydrochlorthiazide SCHEMBL10585431 | 0.95 | ALDH1A1 (0.32) | ALDH1A1LMNA | |
| Hydrochlorthiazide SCHEMBL2581931 | 0.90 | — | — | |
| Hydrochlorthiazide SCHEMBL2496915 | 0.88 | — | — | |
| Hydrochlorthiazide SCHEMBL27890005 | 0.88 | FFAR3 (0.33) | ALDH1A1 | |
| Hydrochlorthiazide SCHEMBL28321063 | 0.88 | — | — | |
| Hydrochlorthiazide SCHEMBL28284942 | 0.86 | ALDH1A1 (0.30) | ALDH1A1 | |
| Hydrochlorthiazide SCHEMBL15571830 | 0.86 | FFAR3 (0.32) | ALDH1A1 | |
| Hydrochlorthiazide SCHEMBL27521699 | 0.86 | FFAR3 (0.32) | ALDH1A1 | |
| Hydrochlorthiazide SCHEMBL1422022 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293931-A1 | Methods and compositions for the removal of nucleic acid amplification inhibitors | LOS ALAMOS NATIONAL SECURITY, LLC | 2008-11-27 | — | — | US | disclosed |
| US-20070065841-A1 | Methods and compositions for the removal of nucleic acid amplification inhibitors | ENERGY, U.S. DEPARTMENT OF | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293931-A1 | Methods and compositions for the removal of nucleic acid amplification inhibitors | POLRMT, FBL, POLL | ALDH1A1 2004/4885LMNA 548/4885 |
| US-20070065841-A1 | Methods and compositions for the removal of nucleic acid amplification inhibitors | POLRMT, FBL, POLL | ALDH1A1 2004/4885LMNA 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.